Researchers reported a rewired 2B4 signaling approach that gives CAR-NK cells a lasting anti-cancer edge. The work builds on the broader CAR-NK field, aiming to improve persistence and activity without the same risks associated with some CAR-T mechanisms. The study aligns with the pipeline push toward next-generation immune effector engineering—where the focus is not only antigen recognition but also the signaling circuitry controlling cytotoxic function and persistence. As CAR platforms move toward combination regimens and solid-tumor targeting, signaling refinements like this may increasingly determine whether responses remain durable.